|3 Months Ended|
Jun. 30, 2022
6. Stock-Based Compensation
Total stock-based compensation expense for the three months ended June 30, 2022 and June 30, 2021 was $0.1 million in both periods.
Bionik did not grant stock options during the three months ended June 30, 2022 and June 30, 2021.
The Company uses the Black-Scholes option pricing model to determine the estimated grant date fair values for stock-based awards. The Black-Scholes option pricing model requires the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. The Company’s assumptions do not include an estimated forfeiture rate.
Option-pricing models require the input of various subjective assumptions, including the option’s expected life and the price volatility of the underlying stock. As it relates to grants previously issued, Bionik’s estimated expected stock price volatility is based on past grants that have been made. Bionik’s expected term of options granted was derived from looking at the Company’s exercise history of its awards granted. The risk-free rate for the expected term of the options is based on the U.S. Treasury yield curve in effect at the time of the grant.
As of June 30, 2022 the total unrecognized compensation cost related to outstanding stock options expected to vest was $0.3 million, which the Company expects to recognize over a weighted-average period of 2 years.
The entire disclosure for share-based payment arrangement.
Reference 1: http://www.xbrl.org/2003/role/disclosureRef